Evidence map›Paper›PMID 36175706›Full record

ArticleMedical oncology (Northwood, London, England)2022

Correction: Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion.

Tian-Yan Luan, Tie-Nian Zhu, Yu-Jie Cui, Gang Zhang, Xue-Jing Song, Dong-Mei Gao, Yi-Mei Zhang, Qing-Lan Zhao, Shuang Liu, Tong-Yi Su and 1 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Tian-Yan LuanDepartment of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Tie-Nian ZhuDepartment of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. zhutienian@163.com.
Yu-Jie CuiDepartment of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Gang ZhangDepartment of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Xue-Jing SongDepartment of Oncology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China.
Dong-Mei GaoDepartment of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China.
Yi-Mei ZhangDepartment of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China.
Qing-Lan ZhaoDepartment of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China.
Shuang LiuDepartment of Pathology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China.
Tong-Yi SuDepartment of Medical Oncology, Bethune International Peace Hospital, Shijiazhuang, 050082, Hebei, China.
Rui-Jing ZhaoKey Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Department of Immunology, Hebei Medical University, Shijiazhuang, 050017, Hebei, China. 6810c@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.